leadf
logo-loader
viewOpen Orphan PLC

Venn Life Sciences holds just over a quarter of new AIM listing Integumen

It formerly held just under 42% of the healthcare products business, which has raised £2.25mln from the float and has a market capitalisation of £8.25mln.

rsz_shutterstock_220316887.jpg
The IPO completes the last phase in the divestment of Venn's Innovenn unit

Contract researcher Venn Life Sciences PLC (LON:VENN) now owns 25.59% of newly-listed Integumen, which made its AIM debut Wednesday.

It formerly held just under 42% of the healthcare products business, which has raised £2.25mln from the float and has a market capitalisation of £8.25mln.

“The admission of Integumen to trading on AIM completes the restructuring by Venn of it's interest in its former innovation division, Innovenn,” Venn said in a stock exchange statement.

Quick facts: Open Orphan PLC

Price: 15.25 GBX

AIM:ORPH
Market: AIM
Market Cap: £101.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

on 08/10/2020

2 min read